Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Overview Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Companies Involved in Therapeutics Development Chiesi Farmaceutici SpA Dompe Farmaceutici SpA Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Drug Profiles cenegermin - Drug Profile Product Description Mechanism Of Action R&D Progress Drugs to Antagonize P75 Neurotrophin Receptor for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress LEVI-04 - Drug Profile Product Description Mechanism Of Action R&D Progress LM-11A31BHS - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Agonize NGFR for Wounds - Drug Profile Product Description Mechanism Of Action R&D Progress Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Dormant Products Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Discontinued Products Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Product Development Milestones Featured News & Press Releases Sep 14, 2017: Levicept Starts First-in-Human Phase I Trial of LEVI-04, A Novel Fusion Protein Therapy for Chronic Pain Jul 20, 2017: Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompe Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy Jul 10, 2017: Dompe Farmaceutici Receives EU marketing authorization For OXERVATE May 23, 2017: Dompe Receives Positive CHMP Opinion in Europe For Oxervate (Cenegermin Eye Drops) For the Treatment of Adult Patients with Moderate or Severe Neurotrophic Keratitis May 19, 2017: The European Medicines Agency: New medicine for rare eye disease Dec 12, 2016: EMA Validates the Marketing Authorisation Application for Cenegermin Eye Drops (Oxervate) Submitted by Dompé Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency Nov 22, 2014: Italian research at the SOI Congress: focus on therapeutic prospects of NGF, the innovative molecule developed on the basis of the studies by Rita Levi Montalcini in ophthalmology Sep 25, 2014: EuCornea: Dompe wins the “Best Poster Award” for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis Apr 03, 2014: First Patient is Enrolled in Lumos Study. Objective: to Evaluate Safety and Potential Efficacy of rhNGF in the Treatment of Retinitis Pigmentosa Sep 11, 2013: Dompé Announces the Food and Drugs Administration Has Granted Orphan Drug Designation to its rhNGF-based Treatment for Retinitis Pigmentosa Jul 01, 2013: Dompé Announces the EMA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis Sep 07, 2012: Dompé Initiates Phase I Clinical Trial On Use Of Recombinant Human Nerve Growth Factor For Treating Neurotrophic Keratitis Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Chiesi Farmaceutici SpA, H2 2017 Pipeline by Dompe Farmaceutici SpA, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Discontinued Products, H2 2017 List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Mechanism of Actions, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

Chiesi Farmaceutici SpA Dompe Farmaceutici SpA